BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» EHA 2021: Sanofi plots H2 refile for CAD drug sutimlimab after announcing further phase III data
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
EHA 2021: Sanofi plots H2 refile for CAD drug sutimlimab after announcing further phase III data
June 11, 2021
By
Richard Staines
No Comments
Sanofi SA has announced new pivotal data that will form the basis of a refiling of rare disease drug sutimlimab for people with cold agglutinin disease (CAD).
BioWorld
Clinical
Immune